Brain diseases and disorders are the leading cause of disability, directly affecting one in three Canadians as well as millions of family members, friends, colleagues and caregivers. The Government of Canada recognizes the significant impact on the health of Canadians, and supports Canadian research on the brain and related diseases and disorders
Category:
Published on: 27 Apr 2017
Discovery expands our understanding of how we remember sound
The ability to remember sounds, and manipulate them in our minds, is incredibly important to our daily lives 鈥� without it we would not be able to understand a sentence, or do simple arithmetic. New research is shedding light on how sound memory works in the brain, and is even demonstrating a means to improve it.
Category:
Published on: 27 Mar 2017
March 26 is Purple Day for Epilepsy, a day to support epilepsy awareness worldwide
The Neuro has been a world leader in epilepsy treatment and research for more than 60 years. Indeed, the 鈥淢ontreal Procedure鈥� developed by The Neuro鈥檚 founder, Dr. Wilder Penfield, and his colleagues has become the standard operating procedure for the surgical treatment of epilepsy. The Neuro was also a pioneering institute in exploiting electroencephalography (EEG) and magnetic resonance imaging (MRI) to study and treat epilepsy.
Published on: 26 Mar 2017
Deep learning transforming neuroscience research
In an article published in Nature on Feb. 15, 2017, researchers, including principal investigators from the Montreal Neurological Institute鈥檚 McConnell Brain Imaging Centre (BIC), used magnetic resonance imaging (MRI) to predict the development of autism in babies.
Category:
Published on: 20 Mar 2017
Health Science Leaders Join Forces to Accelerate Development of Treatments for Neurological Diseases
Montreal, Quebec and Vancouver, British Columbia 鈥� Working together to accelerate research into neurological diseases, three leading players in Canada鈥檚 health sciences sector are joining forces in a unique multi-million dollar partnership to create a novel drug development platform that will help advance new therapeutics for some of the most debilitating conditions such as amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig鈥檚 disease, and Parkinson鈥檚 disease.
Category:
Published on: 16 Mar 2017
Discovery could be key to treating brain and spinal cord injury
A foray into plant biology led one researcher to discover that a natural molecule can repair axons, the thread-like projections that carry electrical signals between cells. Axonal damage is the major culprit underlying disability in conditions such as spinal cord injury and stroke.
Category:
Published on: 8 Mar 2017
Research and clinical care complement each other at The Neuro
February 28th was Rare Diseases Day, an opportunity to recognize a class of disease that is often overlooked. In the past five years, the Montreal Neurological Institute and Hospital (The Neuro) has made the study and treatment of rare diseases a major priority, hiring new specialists and support staff and coordinating activity under a new research group.
Category:
Published on: 28 Feb 2017
In September 2016, the federal government made an unparalleled investment in research and innovation, announcing $84 million in funding over seven years for 成人VR视频鈥檚 Healthy Brains for Healthy Lives initiative, as part of the Canada First Research Excellence Fund (CFREF) program. Following this announcement, a committee for the selection of the HBHL Managing Director engaged in an extensive search and interview process. The Chair of the Selection Committee, Vice-Principal Rosie Goldstein, is now pleased to announce the appointment of Dr.
Category:
Published on: 20 Feb 2017
In September 2016, the federal government made an unparalleled investment in research and innovation, announcing $84 million in funding over seven years for 成人VR视频鈥檚 Healthy Brains for Healthy Lives initiative, as part of the Canada First Research Excellence Fund (CFREF) program. Following this announcement, a committee for the selection of the HBHL Managing Director engaged in an extensive search and interview process. The Chair of the Selection Committee, Vice-Principal Rosie Goldstein, is now pleased to announce the appointment of Dr.
Category:
Published on: 20 Feb 2017
CQDM and Brain Canada join forces again in the funding of two new research projects to address unmet needs in brain research
CQDM and Brain Canada are proud to announce the funding of two new multi-disciplinary and multi-institutional research projects under the second edition of their Focus on Brain strategic initiative. The partners will award a total of $3M to two research teams to develop cutting-edge tools, technologies and platforms designed to accelerate the discovery of new drugs for brain and nervous system disorders.
Category:
Published on: 2 Feb 2017
An all-star lineup of experts in the fields of sports and neurology will share a stage on Jan. 27 to discuss concussions, a serious injury that has only recently been getting the attention it deserves.
Category:
Published on: 11 Jan 2017
The聽85th聽Congr猫s annuel de l鈥橝ssociation francophone pour le savoir聽(Acfas) may be five months away, but 成人VR视频 is already busy getting ready to host what is the largest French-language interdisciplinary conference in the world.
Category:
Published on: 10 Jan 2017
Researchers urged not to miss Nov. 1 deadline for colloquia proposals.
Category:
Published on: 10 Jan 2017
Have you ever met someone who just wasn鈥檛 into music? They may have a condition called specific musical anhedonia, which affects three-to-five per cent of the population.
Researchers at the University of Barcelona and the Montreal Neurological Institute and Hospital of 成人VR视频 have discovered that people with this condition showed reduced functional connectivity between cortical regions responsible for processing sound and subcortical regions related to reward.
Category:
Published on: 4 Jan 2017
Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Category:
Published on: 22 Dec 2016
Pages
